FlyBase Allele Report: Hsap\TARDBP[UAS.cEa]

General Information

Symbol

Hsap\TARDBP^UAS.cEa

Species

H. sapiens

Name

Saccharomyces cerevisiae UAS construct a of Elden

FlyBase ID

FBal0270163

Feature type

allele

Associated gene

Hsap\TARDBP

Associated Insertion(s)

Carried in Construct

P{UAS-TDP-43}

Also Known As

UAS-TDP-43, UAS-hTDP-43, UAS-TDP43, UAS-TARDBP

Key Links

Transgenic product class

wild_type

(Elden et al., 2010)

Mutagen

in vitro construct

Nature of the Allele

Transgenic product class

wild_type

(Elden et al., 2010)

Mutagen

in vitro construct

(Elden et al., 2010)

Progenitor genotype

Carried in construct

P{UAS-TDP-43}

Cytology

Description

UAS regulatory sequences drive expression of Hsap\TARDBP.

(Elden et al., 2010)

Allele components

Component

Use(s)

Regulatory region(s)

UAS

binary expression system - regulatory region

Encoded product / tool

Hsap\TARDBP

Mutations Mapped to the Genome

Curation Data

Type

Location

Additional Notes

References

Variant Molecular Consequences

Associated Sequence Data

DDBJ / EMBL / GenBank

DNA sequence

Protein sequence

UniProtKB/Swiss-Prot

UniProtKB/TrEMBL

Expression Data

Reporter Expression

Additional Information

Statement

Reference

Marker for

Reflects expression of

Reporter construct used in assay

Human Disease Associations

Disease Ontology (DO) Annotations

Models Based on Experimental Evidence ( 1 )

Disease

Evidence

References

model of amyotrophic lateral sclerosis type 10

CEC

(McGurk et al., 2021)

CEA

(Koch and Nagoshi, 2025, Zhao et al., 2023, Cha et al., 2022, François-Moutal et al., 2022, Cha et al., 2020, Lee et al., 2020, Berson et al., 2019, Chung et al., 2018, McGurk et al., 2018, Solomon et al., 2018, Berson et al., 2017, Altanbyek et al., 2016)

CEA with Hsap\ATXN2^32Q.UAS

(Berson et al., 2019)

model of amyotrophic lateral sclerosis

CEA

(Elden et al., 2010)

Modifiers Based on Experimental Evidence ( 1 )

Disease

Interaction

References

model of amyotrophic lateral sclerosis type 10

is exacerbated by Hsap\ATXN2^64CAA.UAS

(McGurk et al., 2021)

is exacerbated by Hsap\ATXN2^64CAG.UAS

(McGurk et al., 2021)

is ameliorated by Ptp61F^HMS00421

(Lee et al., 2020)

is ameliorated by Rack1^HMS01173

(Zhao et al., 2023)

is ameliorated by GstO2^A.UAS

(Cha et al., 2020)

is ameliorated by Marf^UAS.cUa

(Altanbyek et al., 2016)

is exacerbated by Marf^RNAi.UAS.cUa

(Altanbyek et al., 2016)

is ameliorated by Opa1^UAS.cUa

(Altanbyek et al., 2016)

is ameliorated by Drp1^DN.UAS.cUa

(Altanbyek et al., 2016)

is exacerbated by Marf^RNAi.UAS.cUa

(Altanbyek et al., 2016)

is ameliorated by Hsc70-4^UAS.cEa

(Berson et al., 2017)

is ameliorated by Hsp68^UAS.cUa

(Berson et al., 2017)

is ameliorated by Kdm5^HM05155

(Berson et al., 2017)

is exacerbated by Set1^HMS00581

(Berson et al., 2017)

is exacerbated by Chd1^HMS01142

(Berson et al., 2017)

is exacerbated by Wdr82^HMS00718

(Berson et al., 2017)

is exacerbated by ash2^EY03971

(Berson et al., 2017)

is ameliorated by Chd1^UAS.cMa

(Berson et al., 2017)

is ameliorated by Hsc70-3^UAS.cEa

(François-Moutal et al., 2022)

is ameliorated by Tnks^NIG.4719R

(McGurk et al., 2018)

is ameliorated by Ice1^SH09112.N

(Chung et al., 2018)

is exacerbated by Su(Tpl)^G4098

(Chung et al., 2018)

is ameliorated by Su(Tpl)^HMS00277

(Chung et al., 2018)

is ameliorated by Su(Tpl)^S-192

(Chung et al., 2018)

is ameliorated by ear^HMS00107

(Chung et al., 2018)

is ameliorated by lilli^A17-2

(Chung et al., 2018)

is ameliorated by lncRNA:Hsrω⁶⁶

(Chung et al., 2018)

is ameliorated by lncRNA:Hsrω^HMC05093

(Chung et al., 2018)

is ameliorated by snRNA:U12^HMC03841

(Chung et al., 2018)

is ameliorated by Ref1^HMS01301

(Berson et al., 2019)

is exacerbated by hfp^HMS00094

(Berson et al., 2019)

is ameliorated by swm^HMC03677

(Berson et al., 2019)

is exacerbated by nonA^HMC03675

(Koch and Nagoshi, 2025)

is exacerbated by nonA^HMJ23111

(Koch and Nagoshi, 2025)

model of amyotrophic lateral sclerosis

is ameliorated by Atx2^X1

(Elden et al., 2010)

is exacerbated by Atx2^EP3145

(Elden et al., 2010)

is ameliorated by PEK^GL00030

(Kim et al., 2014)

is ameliorated by pAbp^JF03104

(Kim et al., 2014)

is exacerbated by pAbp^UAS.cSa

(Kim et al., 2014)

is exacerbated by Hsap\ATXN2^32Q.UAS

(Kim et al., 2014)

is ameliorated by Rox8^HMS00472

(Kim et al., 2014)

is exacerbated by PPP1R15^HMS00811

(Kim et al., 2014)

Comments on Models/Modifiers Based on Experimental Evidence ( 0 )

Disease-implicated variant(s)

Phenotypic Data

Phenotypic Class

abnormal locomotor behavior, with Scer\GAL4^Toll-6-D42

(Elden et al., 2010)

abnormal locomotor behavior | adult stage, with Scer\GAL4^elav.PLu

(Kim et al., 2014)

abnormal locomotor behavior | adult stage | progressive, with Scer\GAL4^repo.PU

(Lee et al., 2020)

abnormal locomotor behavior | adult stage | RU486 conditional, with Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

abnormal neuroanatomy, with Scer\GAL4^GMR.PF

(Elden et al., 2010)

short lived, with Scer\GAL4^elav.PLu

(Kim et al., 2014)

short lived, with Scer\GAL4^elav-C155

(Elden et al., 2010)

short lived, with Scer\GAL4^repo.PU

(Lee et al., 2020)

visible, with Scer\GAL4^GMR.PU

(Kim et al., 2014)

Phenotype Manifest In

eye, with Scer\GAL4^GMR.PU

(Kim et al., 2014)

NMJ bouton | decreased number | third instar larval stage, with Scer\GAL4^repo.PU

(Lee et al., 2020)

retina, with Scer\GAL4^GMR.PF

(Elden et al., 2010)

Detailed Description

Statement

Reference

Expression of Hsap\TARDBP^UAS.cEa under the control of Scer\GAL4^repo.PU leads to a progressively reduced climbing ability.

(Lee et al., 2020)

Flies expressing Hsap\TARDBP^Scer\UAS.cEa under the control of Scer\GAL4^{elav.Switch.PO} show markedly reduced climbing ability compared to normal flies aged to 14 days when flies are raised with RU486.

Flies expressing Hsap\TARDBP^Scer\UAS.cEa under the control of Scer\GAL4^elav.PLu exhibit reduced adult lifespan and reduced climbing ability. The reduced climbing activity is dramatically mitigated when the flies are fed the PERK inhibitor compound GSK2606415.

(Kim et al., 2014)

Directing expression of Hsap\TARDBP^Scer\UAS.cEa in the eye via Scer\GAL4^GMR.PF causes a progressive, age-dependent degeneration of the retina structure.

Expression of Hsap\TARDBP^Scer\UAS.cEa in the nervous system under the control of Scer\GAL4^elav-C155 induces markedly shortened lifespan.

Expression of Hsap\TARDBP^Scer\UAS.cEa in motor neurons under the control of Scer\GAL4^D42 leads to a progressive loss of motility.

(Elden et al., 2010)

External Data

Linkouts

Interactions

Show genetic interaction network for Enhancers & Suppressors

Phenotypic Class

Enhanced by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has visible phenotype, enhanceable by pAbp^UAS.cSa, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^elav.PLu has short lived phenotype, enhanceable by Hsap\ATXN2^32Q.UAS, Scer\GAL4^elav.PLu

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, enhanceable by Hsap\ATXN2^32Q.UAS, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, enhanceable by PPP1R15^HMS00811, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has visible phenotype, enhanceable by Hsap\ATXN2^32Q.UAS, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has visible phenotype, enhanceable by Hsap\ATXN2^{32Q.ΔLSM.UAS.Tag:MYC}, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PF has abnormal neuroanatomy phenotype, enhanceable by Atx2^EP3145, Scer\GAL4^GMR.PF

(Elden et al., 2010)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^elav-C155 has short lived phenotype, enhanceable by Atx2^EP3145, Scer\GAL4^elav-C155

(Elden et al., 2010)

NOT Enhanced by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^elav.PLu has short lived phenotype, non-enhanceable by Hsap\ATXN2^{32Q.ΔPAM2.UAS.Tag:MYC}, Scer\GAL4^elav.PLu

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, non-enhanceable by Hsap\ATXN2^{32Q.ΔPAM2.UAS.Tag:MYC}, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has visible phenotype, non-enhanceable by Hsap\ATXN2^{32Q.ΔPAM2.UAS.Tag:MYC}, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Suppressed by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^repo.PU has short lived phenotype, suppressible | partially by Ptp61F^HMS00421, Scer\GAL4^repo.PU

(Lee et al., 2020)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^repo.PU has abnormal locomotor behavior | adult stage | progressive phenotype, suppressible | partially by Ptp61F^HMS00421, Scer\GAL4^repo.PU

(Lee et al., 2020)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, suppressible by pAbp^JF03104, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, suppressible | partially by PEK^GL00030, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^{elav.Switch.PO} has abnormal locomotor behavior | adult stage | RU486 conditional phenotype, suppressible | partially by Rox8^HMS00472, Scer\GAL4^{elav.Switch.PO}

(Kim et al., 2014)

Phenotype Manifest In

Enhanced by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by Hsap\ATXN2^32Q.UAS, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by Hsap\ATXN2^{32Q.ΔLSM.UAS.Tag:MYC}, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has eye phenotype, enhanceable by pAbp^UAS.cSa, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PF has retina phenotype, enhanceable by Atx2^EP3145, Scer\GAL4^GMR.PF

(Elden et al., 2010)

NOT Enhanced by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^GMR.PU has eye phenotype, non-enhanceable by Hsap\ATXN2^{32Q.ΔPAM2.UAS.Tag:MYC}, Scer\GAL4^GMR.PU

(Kim et al., 2014)

Suppressed by

Statement

Reference

Hsap\TARDBP^UAS.cEa, Scer\GAL4^repo.PU has NMJ bouton | third instar larval stage | decreased number phenotype, suppressible by Ptp61F^HMS00421, Scer\GAL4^repo.PU

(Lee et al., 2020)

Additional Comments

Genetic Interactions

Statement

Reference

Xenogenetic Interactions

Statement

Reference

Expression of Rox8^HMS00472 greatly suppresses the reduction in climbing ability seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^{elav.Switch.PO} and the flies are raised with RU486.

Expression of PEK^GL00030 greatly suppresses the reduction in climbing ability seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^{elav.Switch.PO} and the flies are raised with RU486.

Expression of PPP1R15^HMS00811 enhances the reduction in climbing ability seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^{elav.Switch.PO} when flies are raised with RU486. The flies almost entirely lose their motility.

Expression of Hsap\ATXN2^32Q.Scer\UAS enhances the eye phenotype seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^GMR.PU. The reduction in lifespan induced by the expression of Hsap\TARDBP^Scer\UAS.cEa (under the control of Scer\GAL4^elav.PLu) and climbing defects (under the control of Scer\GAL4^{elav.Switch.PO} and raised with RU486) are also enhanced.

Expression of Hsap\ATXN2^{32Q.ΔLSM.Scer\UAS.T:Hsap\MYC} enhances the eye phenotype seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^GMR.PU.

Expression of Hsap\ATXN2^{32Q.ΔPAM2.Scer\UAS.T:Hsap\MYC} does not enhance the eye phenotype seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^GMR.PU. The reduction in lifespan induced by the expression of Hsap\TARDBP^Scer\UAS.cEa (under the control of Scer\GAL4^elav.PLu) and climbing defects (under the control of Scer\GAL4^{elav.Switch.PO} and raised with RU486) are also not enhanced.

Expression of pAbp^Scer\UAS.cSa enhances the eye phenotype seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^GMR.PU.

Expression of pAbp^JF03104 suppresses the reduction in climbing ability seen when Hsap\TARDBP^Scer\UAS.cEa is expressed under the control of Scer\GAL4^{elav.Switch.PO} when flies are raised with RU486.

(Kim et al., 2014)

Overexpression of Atx2^EP3145 via Scer\GAL4^GMR.PF enhances the toxicity of Hsap\TARDBP^Scer\UAS.cEa in a markedly dose-dependent manner resulting in more severe retinal degeneration.

Overexpression of Atx2^EP3145 via Scer\GAL4^elav-C155 enhances the toxicity of Hsap\TARDBP^Scer\UAS.cEa in a markedly dose-dependent manner resulting in a further reduction of lifespan.

(Elden et al., 2010)

Complementation and Rescue Data

Comments

Images (0)

Mutant

Wild-type

Stocks (2)

Bloomington

79587

w¹¹¹⁸; P{UAS-TDP-43}37M

79588

w¹¹¹⁸; P{UAS-TDP-43}52/TM3, Sb¹

Notes on Origin

Discoverer

External Crossreferences and Linkouts ( 0 )

Synonyms and Secondary IDs (3)

Reported As

Symbol Synonym

Hsap\TARDBP^Scer\UAS.cEa

Hsap\TARDBP^UAS.cEa

Name Synonyms

Saccharomyces cerevisiae UAS construct a of Elden

Secondary FlyBase IDs

References (20)

Report Sections

Open Close